Inhalation Sciences Sweden AB (publ) releases Half Year Report Q2 2019
Inhalation Sciences CEO Lena Heffler: “A major milestone was reached this quarter with the announcement that we’re commencing a new Study validating PreciseInhale for clinical use. We also received a purchase order for a second PreciseInhale system from a client, a landmark for the company. With clinical validation started and DissolvIt on the way towards commercialization, our goal continues to be achieving cash flow positive results on a full-year basis during 2020.”
Summary of the Reporting period
Highlights during Inhalation Sciences Sweden AB's second quarter:
- On May 7, ISAB received an order for a PreciseInhale system from an existing customer with an order value of approximately SEK 1.6 million. The order includes the platform's unique integrated inhaler actuator and was delivered during the second quarter of 2019.
- The commencement of our Study validating PreciseInhale as a technology for clinical use was announced. The clinical validation study has been financed in its entirety by ISAB divesting 400,000 shares in the associated company Ziccum AB (publ). Sales proceeds amounted to approximately SEK 5.2 million
Net sales SEK 2,695 thousand (769)
Operating profit SEK -821 thousand (-3,799)
Earnings per share before and after dilution SEK 0.44 (-0.43)
Net sales SEK 3,395 thousand (838)
Operating income SEK -3,159 thousand (-7,778)
Earnings per share before and after dilution SEK 0.15 (-0.90)
Read the full report here.
For more information about Inhalation Sciences, please contact: Lena Heffler, CEO E-mail: firstname.lastname@example.org Telephone: +46 (0)70 205 9620Press release in PDF formatPress release in PDF format